Sumitomo Mitsui DS Asset Management’s Novavax NVAX Stock Holding History

Sumitomo Mitsui DS Asset Management’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-3,790	Closed	-$279K	–	778
2022 Q1	$279K	Sell	3,790 -37	-1%	-$3.3K	0.01%	728
2021 Q4	$547K	Hold	3,827	–	–	0.01%	656
2021 Q3	$793K	Sell	3,827 -26	-0.7%	-$5.73K	0.02%	560
2021 Q2	$818K	Buy	+3,853	New	+$706K	0.02%	559

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Sumitomo Mitsui DS Asset Management's NVAX Position: Q2 2022 in Review

Sumitomo Mitsui DS Asset Management sold out of Novavax (NVAX) in Q2 2022, closing a stake of 3,790 shares — an estimated $279K sold.

Sumitomo Mitsui DS Asset Management first reported a position in NVAX in Q2 2021 and held it in 4 quarters. The position peaked at $818K in Q2 2021. 325 funds tracked by Wall St. Rank hold NVAX as of Q2 2022.

Sumitomo Mitsui DS Asset Management reported no remaining Novavax position as of Q2 2022 after selling out during the quarter.
Sumitomo Mitsui DS Asset Management sold 3,790 Novavax shares in Q2 2022, an estimated $279K.
Sumitomo Mitsui DS Asset Management first reported a position in Novavax in Q2 2021 and held it in 4 quarters.
Sumitomo Mitsui DS Asset Management's Novavax position peaked at $818K in Q2 2021.
325 funds tracked by Wall St. Rank held Novavax as of Q2 2022.

Based on Sumitomo Mitsui DS Asset Management's 13F filing for Q2 2022, filed 13 Jul 2022.